Exercise of Options

RNS Number : 0436F

Creo Medical Group PLC

04 March 2020

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Exercise of Options

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, confirms that it has issued, conditional on admission, 36,000 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of employee share options. It is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on 10 March 2020.

Following admission, the Company will have 157,520,021 Ordinary Shares in issue. This figure of 157,520,021 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

Creo Medical Group plc	investors.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys / Cameron MacRitchie (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website,  investors.creomedical.com

 

END

 

 

MSCDZGGFVDLGGZM